|
1
|
Qiu C, Kivipelto M and von Strauss E:
Epidemiology of Alzheimer's disease: Occurrence, determinants and
strategies toward intervention. Dialogues Clin Neurosci.
11:111–128. 2009.
|
|
2
|
Salloway S: Current and future treatments
for Alzheimer's disease. CNS Spectr. 14(8 Suppl 7): 4–7; discussion
16–18. 2009.PubMed/NCBI
|
|
3
|
Yiannopoulou KG and Papageorgiou SG:
Current and future treatments for Alzheimer's disease. Ther Adv
Neurol Disord. 6:19–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aisen PS, Cummings J and Schneider LS:
Symptomatic and nonamyloid/tau based pharmacologic treatment for
Alzheimer disease. Cold Spring Harb Perspect Med. 2:a0063952012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
LaFerla FM, Green KN and Oddo S:
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev
Neurosci. 8:499–509. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li M, Chen L, Lee DH, Yu LC and Zhang Y:
The role of intracellular amyloid beta in Alzheimer's disease. Prog
Neurobiol. 83:131–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carter J and Lippa CF: Beta-amyloid,
neuronal death and Alzheimer's disease. Curr Mol Med. 1:733–737.
2001. View Article : Google Scholar
|
|
8
|
Oakley H, Cole SL, Logan S, Maus E, Shao
P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik
L, et al: Intraneuronal beta-amyloid aggregates, neurodegeneration
and neuron loss in transgenic mice with five familial Alzheimer's
disease mutations: Potential factors in amyloid plaque formation. J
Neurosci. 26:10129–10140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapman PF, White GL, Jones MW,
Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA,
Bliss TV, Hyman BT, et al: Impaired synaptic plasticity and
learning in aged amyloid precursor protein transgenic mice. Nat
Neurosci. 2:271–276. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hung IC, Chang SS, Chang PC, Lee CC and
Chen CY: Memory enhancement by traditional Chinese medicine? J
Biomol Struct Dyn. 31:1411–1439. 2013. View Article : Google Scholar
|
|
11
|
May BH, Lu C, Lu Y, Zhang AL and Xue CC:
Chinese herbs for memory disorders: A review and systematic
analysis of classical herbal literature. J Acupunct Meridian Stud.
6:2–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang L, Zhang J, Zheng K, Shen H and Chen
X: Long-term ginsenoside Rg1 supplementation improves age-related
cognitive decline by promoting synaptic plasticity associated
protein expression in C57BL/6J mice. J Gerontol A Biol Sci Med Sci.
69:282–294. 2014. View Article : Google Scholar
|
|
13
|
Gillis CN: Panax ginseng pharmacology: A
nitric oxide link? Biochem Pharmacol. 54:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee CH and Kim JH: A review on the
medicinal potentials of ginseng and ginsenosides on cardiovascular
diseases. J Ginseng Res. 38:161–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nah SY: Ginseng ginsenoside pharmacology
in the nervous system: Involvement in the regulation of ion
channels and receptors. Frontiers in physiology. 5:982014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee B, Sur B, Park J, Kim SH, Kwon S, Yeom
M, Shim I, Lee H and Hahm DH: Ginsenoside rg3 alleviates
lipopolysaccharide-induced learning and memory impairments by
anti-inflammatory activity in rats. Biomol Ther (Seoul).
21:381–390. 2013. View Article : Google Scholar
|
|
17
|
Song XY, Hu JF, Chu SF, Zhang Z, Xu S,
Yuan YH, Han N, Liu Y, Niu F, He X and Chen NH: Ginsenoside Rg1
attenuates okadaic acid induced spatial memory impairment by the
GSK3beta/tau signaling pathway and the Abeta formation prevention
in rats. Eur J Pharmacol. 710:29–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chu S, Gu J, Feng L, Liu J, Zhang M, Jia
X, Liu M and Yao D: Ginsenoside Rg5 improves cognitive dysfunction
and beta-amyloid deposition in STZ-induced memory impaired rats via
attenuating neuroinflammatory responses. Int Immunopharmacol.
19:317–326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Kan H, Yin Y, Wu W, Hu W, Wang M
and Li W and Li W: Protective effects of ginsenoside Rg1 on chronic
restraint stress induced learning and memory impairments in male
mice. Pharmacol Biochem Behav. 120:73–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nah JJ, Hahn JH, Chung S, Choi S, Kim YI
and Nah SY: Effect of ginsenosides, active components of ginseng,
on capsaicin-induced pain-related behavior. Neuropharmacology.
39:2180–2184. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Long W, Zhang SC, Wen L, Mu L, Yang F and
Chen G: In vivo distribution and pharmacokinetics of multiple
active components from Danshen and Sanqi and their combination via
inner ear administration. J Ethnopharmacol. 156:199–208. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Wang J, Xing Y, Gong L, Li H, Wu
Z, Li Y, Wang J, Wang Y, Dong L and Li S: Effects of ginsenoside
Rg1 or 17β-estradiol on a cognitively impaired, ovariectomized rat
model of Alzheimer's disease. Neuroscience. 220:191–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu G, Wang Y, Li J and Wang J: Chronic
treatment with ginsenoside Rg1 promotes memory and hippocampal
long-term potentiation in middle-aged mice. Neuroscience.
292:81–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Quan Q, Wang J, Li X and Wang Y:
Ginsenoside Rg1 decreases Aβ(1–42) level by upregulating PPARgamma
and IDE expression in the hippocampus of a rat model of Alzheimer's
disease. PloS One. 8:e591552013. View Article : Google Scholar
|
|
25
|
Hong X, Liu J, Zhu G, Zhuang Y, Suo H,
Wang P, Huang D, Xu J, Huang Y, Yu M, et al: Parkin overexpression
ameliorates hippocampal long-term potentiation and β-amyloid load
in an Alzheimer's disease mouse model. Hum Mol Genet. 23:1056–1072.
2014. View Article : Google Scholar
|
|
26
|
Zhu G, Liu Y, Wang Y, Bi X and Baudry M:
Different patterns of electrical activity lead to long-term
potentiation by activating different intracellular pathways. J
Neurosci. 35:621–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu J, Yan X, Li L, Zhu Y, Qin K, Zhou L,
Sun D, Zhang X, Ye R and Zhao G: Ginsennoside rd attenuates
cognitive dysfunction in a rat model of Alzheimer's disease.
Neurochem Res. 37:2738–2747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu J, Li W, Feng SH, Wang M and He ZY:
Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid
precursor protein via a cholesterol-dependent pathway. Genet Mol
Res. 13:3586–3598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao H, Li Q, Pei X, Zhang Z, Yang R, Wang
J and Li Y: Long-term ginsenoside administration prevents memory
impairment in aged C57BL/6J mice by up-regulating the synaptic
plasticity-related proteins in hippocampus. Behav Brain Res.
201:311–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao HF, Li Q and Li Y: Long-term
ginsenoside administration prevents memory loss in aged female
C57BL/6J mice by modulating the redox status and up-regulating the
plasticity-related proteins in hippocampus. Neuroscience.
183:189–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang XY, Chen J and Zhang JT: Effect of
ginsenoside Rg1 on learning and memory impairment induced by
beta-amyloid peptide (25–35) and its mechanism of action. Yao Xue
Xue Bao. 36:1–4. 2001.In Chinese.
|
|
32
|
Chen LM, Lin ZY, Zhu YG, Lin N, Zhang J,
Pan XD and Chen XC: Ginsenoside Rg1 attenuates β-amyloid generation
via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695
cells. Eur J Pharmacol. 675:15–21. 2012. View Article : Google Scholar
|
|
33
|
Fang F, Chen X, Huang T, Lue LF, Luddy JS
and Yan SS: Multi-faced neuroprotective effects of Ginsenoside Rg1
in an Alzheimer mouse model. Biochim Biophys Acta. 1822:286–292.
2012. View Article : Google Scholar :
|
|
34
|
Wang YH and Du GH: Ginsenoside Rg1
inhibits beta-secretase activity in vitro and protects against
Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res.
11:604–612. 2009. View Article : Google Scholar
|
|
35
|
Shi C, Zheng DD, Fang L, Wu F, Kwong WH
and Xu J: Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP
via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim
Biophys Acta. 1820:453–460. 2012. View Article : Google Scholar
|
|
36
|
Li X, Zhang X, Yuan H and Quan Q:
Experimental research on effect of gensenoside Rg1 on expressions
of P-Tau and caspase-3 in brain slices from AD model rats. Zhongguo
Zhong Yao Za Zhi. 35:369–372. 2010.In Chinese. PubMed/NCBI
|
|
37
|
Shi YQ, Huang TW, Chen LM, Pan XD, Zhang
J, Zhu YG and Chen XC: Ginsenoside Rg1 attenuates amyloid-beta
content, regulates PKA/CREB activity and improves cognitive
performance in SAMP8 mice. J Alzheimer's Dis. 19:977–989. 2010.
|
|
38
|
Li X, Liu Y, Zhang X, Yuan H and Quan Q:
Effect of ginsenoside Rg1 on expressions of phosphory protein tau
and N-methyl-D-aspartate receptor subunits NR1 and NR2B in rat
brain slice model of Alzheimer's disease. Zhongguo Zhong Yao Za
Zhi. 35:3339–3343. 2010.In Chinese.
|
|
39
|
Shi C, Na N, Zhu X and Xu J: Estrogenic
effect of ginsenoside Rg1 on APP processing in post-menopausal
platelets. Platelets. 24:51–62. 2013. View Article : Google Scholar
|
